Multiplicom develops, manufactures and commercializes molecular diagnostic assays, provided as kits, which enable personalized medicino.

Founded in 2011 as a spin-off from the University of Antwerp and VIB, Multiplicom achieved end of 2012 its first CE-IVD-certification for the BRCA MASTR Dx assay for breast and ovarian cancer predisposition. It was the first company in Europe achieving a BRCA CE-IVD certification and it continues to develop and market quality controlled MPS-based assays. Therefore, it enables clinical laboratories to diagnose patients with a genetic disease or predisposition, steer cancer therapy, and identify congenital defects early in pregnancy. 

Multiplicom operates a Quality Management System to design, develop, manufacture and distribute CE-IVD products according to ISO 13485:2012.

Their diagnostic products enable medical genetics- and clinical laboratories to meet an increasing demand for molecular diagnostic testing, driven by the scientific evidence that links genetic information to health and disease. Their assays are simple, fast, accurate and flexible. 

Their molecular diagnostic assays allow the:

· determination of whether an individual has an increased genetic risk to develop a disease;

· early detection of congenital genetic defects; and

· identification of mutations that allow physicians to prescribe the most effective drugs for their patients.

Medical genetics and molecular pathology laboratories throughout the world use Multiplicom’s molecular diagnostic assays. These assays allow the optimal amplification of genes of interest prior to targeted re-sequencing using Massively Parallel Sequencing (MPS) for use in the following areas:

· Identification of genomic mutations that predispose for disease: cancer, cardiovascular, metabolic, neurological, renal diseases, etc.

· Identification of somatic mutations associated with cancer to steer therapy: KRAS, P53, BRAF, C-Kit, PIK3CA, EGFR, etc.

· Prenatal diagnosis.